Cancer Archives

News and Trends 8 Aug 2022

Genmab and BioNTech expand collaboration to develop and commercialize immunotherapy candidates

A collaboration between Genmab and BioNTech to develop and commercialize immunotherapies for the treatment of cancer patients has been expanded. Under the expansion announced today (August 5), the companies will jointly work to research, develop, and commercialize novel monospecific antibody candidates for various cancer indications. Since 2015, the companies have been working on the joint […]

August 8, 2022 - 2 minutesmins - By Liza Laws

News and Trends 5 Aug 2022

Beyond Biotech podcast 8: Biotech Growth Trust, Deep Science Ventures, Endogena Therapeutics, eureKARE

This week’s podcast guests are Laura Fletcher, head of business development and strategic partnerships at Deep Science Ventures; Matthias Steger, CEO of Endogena Therapeutics; Rodolphe Besserve, CEO, and Georges Rawadi, chief of biotech studio development, at eureKARE; and Biotech Growth Trust portfolio manager, Geoff Hsu. Endogena Therapeutics to start clinical stage with treatment for blindness […]

August 5, 2022

News and Trends 4 Aug 2022

Sanofi and Innovent Biologics to collaborate on oncology medicines and boost China presence

Sanofi and Innovent Biologics are to collaborate on providing medicines to patients in China with difficult-to-treat cancers. Innovent is a biopharmaceutical company with clinical development capabilities and a broad commercial footprint in China. Both companies said they are committed to accelerating the development and commercialization of two Sanofi key clinical stage oncology assets: Phase III […]

August 4, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 4 Aug 2022

Deal worth $3.7B sealed as Amgen buys biopharma ChemoCentryx

A company producing drugs including TAVNEOS to treat autoimmune diseases, plus others dealing with inflammatory disorders and cancer has been bought by biopharmaceutical company, Amgen for $52 per share. ChemoCentryx and Amgen have entered a definitive agreement worth approximately $3.7 billion. Robert Bradway, chairman and chief executive officer at Amgen, said: “The acquisition of ChemoCentryx […]

August 4, 2022 - 3 minutesmins - By Liza Laws

News and Trends 4 Aug 2022

New breast cancer treatment receives funding

Researchers at Queen’s University Belfast in Northern Ireland have received funding from Breast Cancer Now to search for new treatments inspired by COVID-19 vaccine innovation. The research team will adapt lessons from the development of COVID-19 vaccines in the hunt for new treatments for an aggressive form of breast cancer. Niamh Buckley and Helen McCarthy […]

August 4, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 3 Aug 2022

Patients with advanced cancer set to benefit from ProfoundBio’s new drug

Patients with ovarian, endometrial, breast, non-small cell lung cancers and mesothelioma could benefit from an antibody drug conjugate (ADC) after clearance of an investigational new drug (IND) was approved by the US Food and Drug Administration (FDA). ProfoundBio received the FDA’s ‘study may proceed’ letter today (August 3) to evaluate PRO1184, a folate receptor […]

August 3, 2022 - 2 minutesmins - By Liza Laws

Sanofi drops amcenestrant clinical development program

News and Trends 3 Aug 2022

Allarity Therapeutics drug no longer commercially viable or in shareholders’ best interest

Allarity Therapeutics, after meeting with the US Food and Drug Administration (FDA), has decided a growth factor receptor drug it licensed from Novartis is no longer commercially viable or in the best interests of its shareholders. A type C advisory meeting was held between Allarity and the FDA to discuss a development path for dovitinib. […]

August 3, 2022 - 4 minutesmins - By Liza Laws

car-t therapy, combination therapy, car-t cell therapy, cancer therapy, blood cancer

More News! 3 Aug 2022

Allarity Therapeutics takes advice from its board and switches focus to combination therapies

US-based Allarity Therapeutics has made a decision to change tack and focus on combination therapy approaches while making the most of its current assets. The company says the new strategy, driven by its board of directors, aligns with the ongoing shift in oncology standard-of-care moving away from monotherapies. Instead it will veer towards more promising […]

August 3, 2022 - 3 minutesmins - By Liza Laws

More News! 3 Aug 2022

Orca Bio announces Precision-T phase 3 study open and enrolling patients across US transplant centers

US-based Orca Bio, today announced Precision-T, its pivotal phase 3 study, is open, enrolling and treating 174 leukemia patients at more than 20 clinical trial sites. Precision-T is a randomized, open-label multi-center study that is evaluating the safety and efficacy of Orca Bio’s lead investigational high-precision cell therapy, Orca-T, compared to standard of care allogeneic […]

August 3, 2022 - 2 minutesmins - By Liza Laws

News and Trends 3 Aug 2022

siRNA company Eleven Therapeutics seals $22M funding

Eleven Therapeutics has raised a total of $22 million in seed funding. Among the roster of funders is the Bill & Melinda Gates Foundation, which committed $9 million in funding to Eleven, including $5 million towards future equity investment supporting the development of a first-of-its-kind platform that designs small interfering RNAs (siRNAs) with ultra-long durability […]

August 3, 2022 - 3 minutesmins - By Jim Cornall

In Depth 3 Aug 2022

The biggest European biotech investments in July 2022

The mRNA firm Normax Biomed snagged Europe’s biggest private biotech investment in July 2022, with runners-up including AgomAb and Tropic Biosciences. Life sciences manufacturing companies saw a big windfall in Europe in July 2022 as the Cork-based Normax Biomed bagged around $301 million. The firm is establishing modular manufacturing facilities that could provide mRNA vaccines […]

August 3, 2022 - 3 minutesmins - By Jonathan Smith

News and Trends 2 Aug 2022

MAIA Biotechnology raises $10M from public offering

U.S. clinical stage company MAIA Biotechnology, Inc. has closed its initial public offering of 2,000,000 shares of the company’s common stock at a public offering price of $5.00 per share. The gross proceeds from the initial public offering were $10 million, prior to deducting underwriting discounts, commissions, and other offering expenses. The company has granted […]

August 2, 2022 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

Genmab and BioNTech expand collaboration to develop and commercialize immunotherapy candidates

Beyond Biotech podcast 8: Biotech Growth Trust, Deep Science Ventures, Endogena Therapeutics, eureKARE

Sanofi and Innovent Biologics to collaborate on oncology medicines and boost China presence

Deal worth $3.7B sealed as Amgen buys biopharma ChemoCentryx

New breast cancer treatment receives funding

Patients with advanced cancer set to benefit from ProfoundBio’s new drug

Allarity Therapeutics drug no longer commercially viable or in shareholders’ best interest

Allarity Therapeutics takes advice from its board and switches focus to combination therapies

Orca Bio announces Precision-T phase 3 study open and enrolling patients across US transplant centers

siRNA company Eleven Therapeutics seals $22M funding

The biggest European biotech investments in July 2022

MAIA Biotechnology raises $10M from public offering

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!